THE SINGULAR FOCUS on treating cholesterol as a means to prevent heart attacks is leading to the deaths of millions of people because the real underlying cause of the majority of heart disease is not being diagnosed or treated by most physicians. For example, I recently saw a patient named Jim who had “normal” cholesterol levels yet was taking the most powerful statin on the market, Crestor. Despite this aggressive pharmaceutical treatment, this man was headed for a serious heart attack. Jim’s doctors had missed his real disease risks by focusing on and treating his cholesterol levels. All the while they were ignoring the most important condition that put him at dramatically higher risk of heart attacks, diabetes, cancer, anddementia. In a moment I will explain what this condition is and what you can do about it.
This craze for treating cholesterol has lead to an onslaught of pharmaceuticals designed to “lower cholesterol.” Statins are now the number one selling class of drugs in the nation and new cholesterol medications are produced every day. The latest in a new class of “super” cholesterol drugs, CETP inhibitors, now in the drug approval pipeline from Merck (anacetrapib) burst into the news recently with exclamations from typically restrained scientists. Data on this new drug was recently published in the New England Journal of Medicine and presented at the American Heart Association conference in Chicago.
The study found a 39.8 percent reduction in LDL (or bad cholesterol) and a 138 percent increase in HDL or good cholesterol.(i) Sure, the medications lowered cholesterol. However, the study was not large enough or long enough to answer the most important question: Did the drug results in fewer heart attacks and deaths. Despite this glaring omission, the scientists reporting on these results used words such as “spectacular”, “giddy”, “enormous”, “most excited in decades” to describe their enthusiasm over the medication. Of course, the researchers (as I described in a recent post “Dangerous Spin Doctors”) were on the payroll of Merck who funded the study.
Metabolic syndrome is the leading cause of heart disease, diabetes, and a variety of other chronic illnesses in this country.
Why Lowering Cholesterol May Not Lower the Risk of Death
Unfortunately, these scientists seemed to have short-term memory loss. Just three short years ago in 2007, another new “wonder” drug from Pfizer (torcetrapib) which worked on the same mechanism that anacetrapib does, was found to dramatically lower LDL and raise HDL cholesterol, just like this new drug from Merck. There was only one small problem—in those taking the drug, deaths from heart attacks increased 25 percent, deaths from heart disease increased 40 percent and overall deaths increased 200 percent.(ii) After spending $800 million in development Pfizer had to walk away from the drug. Oops. How can a drug that does all the right things (dramatically lowering bad cholesterol and raise good cholesterol) actually cause MORE heart disease and deaths?
The answer is simple. Drugs don’t treat the underlying causes of chronic illness. It is not our genes which haven’t changed much in 20,000 years, although they may predispose us to environmental and lifestyle triggers of illness. The causes of chronic disease are rooted in what we eat, how much we move, how we face stress, how connected we are to our communities and toxic chemicals and metals in our environment.
A wry editorial in the New England Journal of Medicine many years ago remarked that doctors should use new drugs as soon as they come on the market before side effects develop. Perhaps that’s what the authors of this study are proposing we do with anacetrapib.
Read the rest of this article here: http://drhyman.com/seven-tips-to-fix-your-cholesterol-without-medication-3997/